Skip to content

Pfizer had clues its blockbuster drug could prevent Alzheimer’s. Why didn’t it tell the world?

June 12, 2019

From The Washington Post website

A team of researchers inside Pfizer made a startling find in 2015: The company’s blockbuster rheumatoid arthritis therapy Enbrel, a powerful anti-inflammatory drug, appeared to reduce the risk of Alzheimer’s disease by 64 percent.

The results were from an analysis of hundreds of thousands of insurance claims. Verifying that the drug would actually have that effect in people would require a costly clinical trial — and after several years of internal discussion, Pfizer opted against further investigation and chose not to make the data public, the company confirmed.

Continue reading

From → Health & Safety

Comments are closed.